Abstract: The invention identifies Syngap1 dysfunctions as causative of mental retardation. Described are methods of detecting mental retardation and methods of detecting non-syndromic mental retardation (NSMR) in a human subject. Particular methods comprise sequencing a human subject's genomic DNA for comparison with a control sequence from an unaffected individual. Also described are probes, kits, antibodies and isolated mutated Syngap1 proteins.

Abstract: The invention concerns a remote-controlled vehicle designed to be mounted on a support and capable of clearing an obstacle on the support. The vehicle comprises first and second mobile frames. At least one articulated arm is mounted mobile on the first frame and a wheel is mounted on the articulated arm to maintain the vehicle on the support. A fastening means co-operates with the wheel and is adapted to retain the wheel on the support. At least one temporary support arm is mounted mobile on the second frame. The temporary support arm comprises retaining means for maintaining the vehicle on the support. The vehicle comprises motor means connected between the frames and the arms for moving same with respect to one another so as to clear an obstacle encountered on the support.

Abstract: The invention concerns a remote-controlled vehicle designed to be mounted on a support and capable of clearing an obstacle on the support. The vehicle comprises first and second mobile frames. At least one articulated arm is mounted mobile on the first frame and a wheel is mounted on the articulated arm to maintain the vehicle on the support. A fastening means co-operates with the wheel and is adapted to retain the wheel on the support. At least one temporary support arm is mounted mobile on the second frame. The temporary support arm comprises retaining means for maintaining the vehicle on the support. The vehicle comprises motor means connected between the frames and the arms for moving same with respect to one another so as to clear an obstacle encountered on the support.

Abstract: Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylpropionyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the three amino acid residues immediately preceeding R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.

Abstract: Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 -B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylacetyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the four amino acid residues immediately preceding R.sup.11 may optionally be deleted, R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.